Produkty 1085273-49-9

CAS 1085273-49-9 występuje w naszej ofercie pod nazwami: 23S–hydroxyl–11，15–dioxo–ganoderic acid DM, 23S-hydroxyl-11,15-dioxo-ganoderic acid DM, 23S-hydroxyl-11,15-dioxo-ganoderic acid DM, ≥98%, ≥98%. Oferty producentów: GLPBio, Biosynth, Chemat, MedChemExpress. Dostępne opakowania: 5mg, 10mg, 25mg, 50mg, 1 mg, 5 mg.

23S–hydroxyl–11，15–dioxo–ganoderic acid DM
GLPBio
  • opakowanie: 5mg
  • Warianty: 1
od 2520,73
Zobacz produkt
23S-hydroxyl-11,15-dioxo-ganoderic acid DM
Biosynth, MedChemExpress
  • opakowanie: 10mg, 5mg, 25mg, 50mg
  • Warianty: 6
od 2037,97
Zobacz produkt
23S-hydroxyl-11,15-dioxo-ganoderic acid DM, ≥98%, ≥98%
Chemat
  • opakowanie: 5mg
  • Warianty: 1
od 2723,60
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(E,4S,6R)-4-hydroxy-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid (CAS 1085273-49-9) to związek chemiczny o wzorze sumarycznym C30H40O7 i masie molowej 512.6 g/mol. Nazwa systematyczna IUPAC: (E,4S,6R)-4-hydroxy-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid. InChIKey: PILMPTUAXYPAME-KKYGLDRZSA-N.

Dane identyfikacyjne
Wzór sumarycznyC30H40O7
Masa molowa512.6 g/mol
Nazwa IUPAC(E,4S,6R)-4-hydroxy-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid
InChIKeyPILMPTUAXYPAME-KKYGLDRZSA-N
SMILESC[C@H](C[C@@H](/C=C(\C)/C(=O)O)O)[C@H]1CC(=O)[C@@]2([C@@]1(CC(=O)C3=C2C(=O)C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C

Dane obliczone przez PubChem (NCBI)

Synonimy: 23S-hydroxy-3,7,11,15-tetraoxo-lanost-8,24E-diene-26-oicacid, 23S-hydroxy-11,15-dioxo-ganoderic acid DM, orb1684880, 23S-Hydroxy-3,7,11,15-tetraoxo-lanost-8,24E-diene-26-oic, 23s-hydroxy-3,7,11,15-tetraoxo-lanost-8,24e-diene-26-oic acid
Izomery (ten sam wzór sumaryczny)
(2R,6R)-2-methyl-4-oxo-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid C30H40O7
6-(3-hydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-1,2,3,5,6,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl)-2-methyl-4-oxohept-5-enoic acid C30H40O7
[(1R,2R,5S,6R,10R,11S,12R,15R,16R,18S,19R)-18-acetyloxy-6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.02,10.05,9.015,19]nonadec-8-en-16-yl] acetate C30H40O7
(E)-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxohept-5-enoic acid C30H40O7
(6R)-6-[(5R,7S,10S,13R,14R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12-hexahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid C30H40O7
[(1S,2R,7S,9R,11R,12S,13S,15R,16R)-15-[(1S)-1-[(2R)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-12-hydroxy-2,16-dimethyl-3-oxo-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-13-yl] acetate C30H40O7
(Z,2R)-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxohept-5-enoic acid C30H40O7
(E)-6-[(2R,3S,7R,9S,11R,15R,17R)-9,17-dihydroxy-2,6,6,11,15-pentamethyl-5,12-dioxo-14-pentacyclo[8.7.0.02,7.03,17.011,15]heptadec-1(10)-enyl]-2-methyl-4-oxohept-5-enoic acid C30H40O7